上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

INDICATIVE ANNOUNCEMENT ON OBTAINING CLINICAL TRIAL APPROVAL FOR RECOMBINANT ANTI-CD30 HUMAN-MOUSE CHIMERIC MONOCLONAL ANTIBODY-MCC-DM1 INJECTION

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the "**Company**") on a voluntary basis.

The board of the directors (the "**Board**") of the Company is pleased to announce that, as at the date of this announcement, the Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal Antibody-MCC-DM1 Injection (the "**Drug**"), which was jointly developed by the Company and Shanghai Jiaolian Drug Development Co., Ltd.* (上海交聯藥物研發有限公司) ("**Shanghai Jiaolian**"), has obtained the clinical trial approval issued by the State Drug Administration, of which the number is 2018L02789.

The Drug is a new human recombinant monoclonal antibody-drug product which is intended for anaplastic large cell lymphoma, Hodgkin lymphoma and cutaneous T cell lymphoma. On 5 June 2012, the Company entered into the cooperative research agreement with Shanghai Jiaolian, pursuant to which each party shall undertake their own part of the research and development work and bear the corresponding expenses. Shanghai Jiaolian is a company engaged in the development of small molecule drug and antibody-drug conjugate drugs. It became a wholly-owned subsidiary of Shanghai Pharmaceuticals

Holding Co., Ltd.* (上海醫藥集團股份有限公司) from 3 December 2013. There was no transactions or payments between both parties before the drug clinical trial approval is obtained.

Details of the percentage of expenses borne by each party as well as the allocation of the interest of the Drug will be separately agreed through negotiations according to the progress of development. The Company will further fulfil its disclosure obligations in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in due course (if required).

The drug needs further clinical trial research and obtaining the additional approvals issued by the State Drug Administration. After that, the Company have to obtain the Drug Manufacturing Certificate for the Drug before it could be launched in the market. It might take long time to obtain the above approvals so that the launching time of the Drug could not be confirmed at the moment.

The approval for the clinical trial of the Drug will effectively promote the development of the genetic technology platform projects of the Company, bringing a positive impact on the future production and operation of the group.

By order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)
Mr. Su Yong (Executive Director)
Mr. Zhao Da Jun (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Zhou Zhong Hui (Independent Non-executive Director)
Mr. Lam Yiu Kin (Independent Non-executive Director)
Mr. Xu Qing (Independent Non-executive Director)
Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

18 July 2018
** For identification purpose only*